Bank of Montreal
PHAS

Bank of Montreal’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Bank of Montreal’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-365
Closed -$1K – 5336
2021
Q1 		$1K Sell
365
-1,938
-84% -$7.87K ﹤0.01% 5028
2020
Q4 		$9K Buy
2,303
+1,598
+227% +$5.72K ﹤0.01% 4692
2020
Q3 		$2K Sell
705
-452
-39% -$1.82K ﹤0.01% 4666
2020
Q2 		$5K Buy
+1,157
New +$5.12K ﹤0.01% 4435
2020
Q1 		– Sell
-1,748
Closed -$11K – 4925
2019
Q4 		$11K Buy
1,748
+534
+44% +$2.2K ﹤0.01% 4552
2019
Q3 		$5K Buy
1,214
+69
+6% +$550 ﹤0.01% 4569
2019
Q2 		$15K Buy
+1,145
New +$14K ﹤0.01% 4353

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Bank of Montreal's PHAS Position: Q2 2021 in Review

Bank of Montreal sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2021, closing a stake of 365 shares — an estimated $1K sold.

Bank of Montreal first reported a position in PHAS in Q2 2019 and held it in 7 quarters. The position peaked at $15K in Q2 2019. 55 funds tracked by Wall St. Rank hold PHAS as of Q2 2021.

  • Bank of Montreal reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Bank of Montreal sold 365 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $1K.
  • Bank of Montreal first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 7 quarters.
  • Bank of Montreal's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $15K in Q2 2019.
  • 55 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Bank of Montreal's 13F filing for Q2 2021, filed 12 Aug 2021.